Summary
Overview of U.S. Food and Drug Administration’s approach to Artificial Intelligence/Machine Learning in Software as a Medical Device, including policy initiatives, guiding principles, and links to guidance and resources. Describes regulatory considerations for AI/ML devices and ongoing engagement activities.
Healthcare Implications
Provides implementers and developers with reference materials to align Artificial Intelligence/Machine Learning device development and post‑market practices with U.S. Food and Drug Administration expectations.